Erratum: Error in byline: National use of proton pump inhibitors from 2007 to 2011 (JAMA Internal Medicine (2014) 10.1001/jamainternmed.2014.2900);National use of proton pump inhibitors from 2007 to 2011

JAMA Internal Medicine

Volumn 174, Issue 11, 2014, Pages 1856-1858

  Johansen, Michael E ^a   Huerta, Timothy R ^a   Richardson, Caroline R ^b,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d VA Center for Clinical Management Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; DEMOGRAPHY; DRUG COST; DRUG USE; ELIXHAUSER COMORBIDITY INDEX; FEMALE; HEALTH CARE COST; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; SEX DIFFERENCE; SOCIAL STATUS; ECONOMICS; STATISTICAL MODEL; UNITED STATES;

FEMALE; HUMANS; LOGISTIC MODELS; MALE; PROTON PUMP INHIBITORS; UNITED STATES;

EID: 84925282849     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5989     Document Type: Erratum

References (6)

1. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: Comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003;17(10):1237-1245.
2. McDonagh MS, Carson S, Thakurta S. Drug Class Review on Proton Pump Inhibitors. Portland: Oregon Health & Science University; 2009.
3. Hill SC, Zuvekas SH, Zodet MW. Implications of the accuracy of MEPS prescription drug data for health services research. Inquiry. 2011;48(3):242-259.
4. Comorbidity Software. Version 3.7. http://www.hcup-us.ahrq.gov/toolssoftware /comorbidity/Table2-FY12-V3-7.pdf. Accessed January 28, 2014.
5. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012; 307(14):1513-1516.
6. Kesselheim AS. Rising health care costs and life-cycle management in the pharmaceutical market. PLoS Med. 2013;10(6):e1001461.